Skip to main content
Premium Trial:

Request an Annual Quote

Six NIH Units Sign Up for Access to Affymetrix's GeneChip Technology


SANTA CLARA, Calif.--Affymetrix announced that six institutes of the US National Institutes of Health have agreed to a broad GeneChip technology access contract. They include: the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Child Health and Human Development; and, the National Institute of Health Clinical Center.

Under the agreement, NIH researchers will gain broad access to Affymetrix's standard and custom GeneChip arrays, instrumentation, and software to monitor gene expression in research activities. The agreement includes terms and conditions for use of the GeneChip technology, volume discounts, and minimum purchase commitments. The terms and conditions for use of the GeneChip technology by NIH researchers have been specially designed to allow for broad publication of scientific results and to facilitate collaborations with academic, governmental, and commercial scientific colleagues.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.